• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布罗塞尔®(菠萝蛋白酶、七叶皂苷和硒),口服营养补充剂,用于治疗炎症性耳鼻喉科疾病的单药疗法。

Broser® (bromelain, escin and selenium), oral nutraceutical, monotherapy in patients with inflammatory otorhinolaryngological disorders.

机构信息

ENT Department, University of Palermo, Palermo, Italy

Otolaryngology Unit, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy

出版信息

J Biol Regul Homeost Agents. 2019;33(2):609-615.

PMID:30891997
Abstract

Inflammation is a common pathogenic mechanism involved in many otorhinolaryngological (ORL) disorders. Broser® is an oral nutraceutical currently containing bromelain 100 mg, escin 30 mg, and selenium 42.5 mcg. It could exert a safe and effective anti-inflammatory activity by virtue of these components. Therefore, the aim of the current survey, conducted in clinical practice of 84 Italian ORL centers, was to evaluate its safety and efficacy in the treatment of patients.

摘要

炎症是涉及许多耳鼻喉科(ORL)疾病的常见发病机制。Broser® 是一种口服营养保健品,目前含有 100 毫克菠萝蛋白酶、30 毫克七叶皂苷和 42.5 微克硒。这些成分使其具有安全有效的抗炎活性。因此,本次调查在 84 家意大利耳鼻喉科中心的临床实践中进行,旨在评估其在治疗患者中的安全性和疗效。

相似文献

1
Broser® (bromelain, escin and selenium), oral nutraceutical, monotherapy in patients with inflammatory otorhinolaryngological disorders.布罗塞尔®(菠萝蛋白酶、七叶皂苷和硒),口服营养补充剂,用于治疗炎症性耳鼻喉科疾病的单药疗法。
J Biol Regul Homeost Agents. 2019;33(2):609-615.
2
Glucocorticoid-Like Activity of Escin: A New Mechanism for an Old Drug.七叶皂苷的糖皮质激素样作用:一种老药的新机制。
Drug Des Devel Ther. 2021 Feb 24;15:699-704. doi: 10.2147/DDDT.S297501. eCollection 2021.
3
Biochemical studies on the resolution of experimental inflammations in animals treated with bromelain.对用菠萝蛋白酶治疗的动物实验性炎症消退的生化研究。
Exp Med Surg. 1967;25(1):229-35.
4
Broncalt®, class II medical device, in patients with chronic upper airways disease: a survey in clinical practice.二类医疗器械Broncalt®用于慢性上呼吸道疾病患者:一项临床实践调查
Acta Biomed. 2019 Jul 10;90(7-S):30-35. doi: 10.23750/abm.v90i7-S.8655.
5
Broncalt®, class II medical device, in patients with acute upper airways disease: a survey in clinical practice.二类医疗器械Broncalt®在急性上呼吸道疾病患者中的临床应用调查
Acta Biomed. 2019 Jul 10;90(7-S):24-29. doi: 10.23750/abm.v90i7-S.8654.
6
'Complementary ENT': a systematic review of commonly used supplements.“补充性耳鼻喉科”:常用补充剂的系统评价
J Laryngol Otol. 2007 Aug;121(8):779-82. doi: 10.1017/S002221510600449X. Epub 2006 Nov 24.
7
Broncalt®, class II medical device, in patients with chronic relapsed upper airways disease: a survey in clinical practice.二类医疗器械Broncalt®用于慢性复发性上呼吸道疾病患者:一项临床实践调查
Acta Biomed. 2019 Jul 10;90(7-S):36-40. doi: 10.23750/abm.v90i7-S.8656.
8
Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro.七叶皂苷在体内和体外与低剂量糖皮质激素发挥协同抗炎作用。
Phytomedicine. 2011 Feb 15;18(4):272-7. doi: 10.1016/j.phymed.2010.08.013. Epub 2010 Sep 18.
9
Combined treatment with low dose prednisone and escin improves the anti-arthritic effect in experimental arthritis.低剂量泼尼松与七叶皂苷联合治疗可改善实验性关节炎的抗关节炎效果。
Int Immunopharmacol. 2016 Feb;31:257-65. doi: 10.1016/j.intimp.2016.01.006. Epub 2016 Jan 13.
10
Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties.七叶皂苷:对其消肿、抗炎和静脉张力调节特性的综述
Drug Des Devel Ther. 2019 Sep 27;13:3425-3437. doi: 10.2147/DDDT.S207720. eCollection 2019.

引用本文的文献

1
Influence of cigarette smoking on allergic rhinitis: a comparative study on smokers and non-smokers.吸烟对过敏性鼻炎的影响:吸烟者与非吸烟者的对比研究
Acta Biomed. 2019 Jul 10;90(7-S):45-51. doi: 10.23750/abm.v90i7-S.8658.
2
Broncalt®, class II medical device, in patients with chronic upper airways disease: a survey in clinical practice.二类医疗器械Broncalt®用于慢性上呼吸道疾病患者:一项临床实践调查
Acta Biomed. 2019 Jul 10;90(7-S):30-35. doi: 10.23750/abm.v90i7-S.8655.